-Reuters
HC Wainwright & Co. Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $6.